---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-208959"
form_type: "8-K"
ticker: "SGHT"
cik: "0001531177"
company_name: "Sight Sciences, Inc."
filed_at: "2026-05-06T23:59:59+00:00"
generated_at: "2026-05-14T22:37:39.360989+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sight Sciences Q1 revenue up 13% to $19.7M; raises FY 2026 guidance; Alcon damages $55.4M

## Summary
- Q1 revenue $19.7M (+13% YoY); net loss $13.0M ($0.24 loss per share) vs $14.2M loss in prior year.
- Interventional Dry Eye revenue $1.4M (+244% YoY, +87% QoQ); Glaucoma revenue $18.3M (+7% YoY).
- FY 2026 revenue guidance raised to $83M-$89M from $82M-$88M; adj. opex reaffirmed $93M-$96M.
- Final Alcon judgment: $55.4M past damages + 10% ongoing royalty for Hydrus patent infringement (subject to appeal).

## SEC filing metadata
- accession: 0001193125-26-208959
- form_type: 8-K
- ticker: SGHT
- cik: 0001531177
- company_name: Sight Sciences, Inc.
- filed_at: 2026-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1531177/000119312526208959/0001193125-26-208959-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1531177/000119312526208959/sght-20260506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-208959
- JSON: https://secwatch.observer/filing/0001193125-26-208959.json
- Plain text: https://secwatch.observer/filing/0001193125-26-208959.txt

## Key facts
- Earnings Releases
  Sight Sciences, Inc. reported the first quarter ended March 31, 2026 results: revenue $19.7 million, net income Net loss was $13.0 million, EPS loss of $0.24 per share. Guidance raised.
  - Period: the first quarter ended March 31, 2026
  - Revenue: $19.7 million
  - Net income: Net loss was $13.0 million
  - EPS: loss of $0.24 per share
  - Guidance: raised
  - Result: reported results
  source text: results for the first quarter ended March 31, 2026 and raised its revenue guidance for full year 2026. Recent Financial and Business Highlights • Generated total revenue of $19.7 million in the first quarter of 2026, an increase of 13% compared to the same period in the prior year. • Drove Interventional Glaucoma revenue growth of 7% in the first quarter of 2026,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1531177/000119312526208959/0001193125-26-208959-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.